135 related articles for article (PubMed ID: 21913874)
1. Otelixizumab: a novel agent for the prevention of type 1 diabetes mellitus.
Miller SA; St Onge E
Expert Opin Biol Ther; 2011 Nov; 11(11):1525-32. PubMed ID: 21913874
[TBL] [Abstract][Full Text] [Related]
2. Teplizumab for treatment of type 1 diabetes mellitus.
Skelley JW; Elmore LK; Kyle JA
Ann Pharmacother; 2012 Oct; 46(10):1405-12. PubMed ID: 22968521
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of otelixizumab use in new-onset type 1 diabetes mellitus.
Guglielmi C; Williams SR; Del Toro R; Pozzilli P
Expert Opin Biol Ther; 2016 Jun; 16(6):841-6. PubMed ID: 27145230
[TBL] [Abstract][Full Text] [Related]
4. Otelixizumab in the treatment of type 1 diabetes mellitus.
Sprangers B; Van der Schueren B; Gillard P; Mathieu C
Immunotherapy; 2011 Nov; 3(11):1303-16. PubMed ID: 22053883
[TBL] [Abstract][Full Text] [Related]
5. Emerging treatments for the prevention of type 1 diabetes.
Raskin P; Mohan A
Expert Opin Emerg Drugs; 2010 Jun; 15(2):225-36. PubMed ID: 20384544
[TBL] [Abstract][Full Text] [Related]
6. Gevokizumab in type 1 diabetes mellitus: extreme remedies for extreme diseases?
Pafili K; Papanas N; Maltezos E
Expert Opin Investig Drugs; 2014 Sep; 23(9):1277-84. PubMed ID: 25079039
[TBL] [Abstract][Full Text] [Related]
7. Anti-CD3 clinical trials in type 1 diabetes mellitus.
Daifotis AG; Koenig S; Chatenoud L; Herold KC
Clin Immunol; 2013 Dec; 149(3):268-78. PubMed ID: 23726024
[TBL] [Abstract][Full Text] [Related]
8. Preservation of recall immunity in anti-CD3-treated recent onset type 1 diabetes patients.
Alkemade GM; Hilbrands R; Vandemeulebroucke E; Pipeleers D; Waldmann H; Mathieu C; Keymeulen B; Roep BO
Diabetes Metab Res Rev; 2011 Nov; 27(8):925-7. PubMed ID: 22069286
[TBL] [Abstract][Full Text] [Related]
9. Prevention versus intervention of type 1 diabetes.
Brooks-Worrell B; Palmer JP
Clin Immunol; 2013 Dec; 149(3):332-8. PubMed ID: 23803322
[TBL] [Abstract][Full Text] [Related]
10. A randomised, single-blind, placebo-controlled, dose-finding safety and tolerability study of the anti-CD3 monoclonal antibody otelixizumab in new-onset type 1 diabetes.
Keymeulen B; van Maurik A; Inman D; Oliveira J; McLaughlin R; Gittelman RM; Roep BO; Gillard P; Hilbrands R; Gorus F; Mathieu C; Van de Velde U; Wisniacki N; Napolitano A
Diabetologia; 2021 Feb; 64(2):313-324. PubMed ID: 33145642
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and pharmacodynamics of a chimeric/humanized anti-CD3 monoclonal antibody, otelixizumab (TRX4), in subjects with psoriasis and with type 1 diabetes mellitus.
Wiczling P; Rosenzweig M; Vaickus L; Jusko WJ
J Clin Pharmacol; 2010 May; 50(5):494-506. PubMed ID: 19934031
[TBL] [Abstract][Full Text] [Related]
12. Low-dose otelixizumab anti-CD3 monoclonal antibody DEFEND-1 study: results of the randomized phase III study in recent-onset human type 1 diabetes.
Aronson R; Gottlieb PA; Christiansen JS; Donner TW; Bosi E; Bode BW; Pozzilli P;
Diabetes Care; 2014 Oct; 37(10):2746-54. PubMed ID: 25011949
[TBL] [Abstract][Full Text] [Related]
13. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes.
Keymeulen B; Vandemeulebroucke E; Ziegler AG; Mathieu C; Kaufman L; Hale G; Gorus F; Goldman M; Walter M; Candon S; Schandene L; Crenier L; De Block C; Seigneurin JM; De Pauw P; Pierard D; Weets I; Rebello P; Bird P; Berrie E; Frewin M; Waldmann H; Bach JF; Pipeleers D; Chatenoud L
N Engl J Med; 2005 Jun; 352(25):2598-608. PubMed ID: 15972866
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of low-dose otelixizumab anti-CD3 monoclonal antibody in preserving C-peptide secretion in adolescent type 1 diabetes: DEFEND-2, a randomized, placebo-controlled, double-blind, multi-centre study.
Ambery P; Donner TW; Biswas N; Donaldson J; Parkin J; Dayan CM
Diabet Med; 2014 Apr; 31(4):399-402. PubMed ID: 24236828
[TBL] [Abstract][Full Text] [Related]
15. [Clinical study of the month. Attempt at preservation of B cells during the initial phase of type 1 diabetes: negative results with ultralente insulin, but promising results with an anti-CD3 monoclonal antibody].
Philips JC; Scheen AJ;
Rev Med Liege; 2002 Jun; 57(6):413-7. PubMed ID: 12180038
[TBL] [Abstract][Full Text] [Related]
16. Emerging drugs for the treatment of type 1 diabetes mellitus: a review of phase 2 clinical trials.
Min T; Bain SC
Expert Opin Emerg Drugs; 2023 Mar; 28(1):1-15. PubMed ID: 36896700
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of anti-CD3 monoclonal antibodies in delaying the progression of recent-onset type 1 diabetes mellitus: A systematic review, meta-analyses and meta-regression.
Ashraf MT; Ahmed Rizvi SH; Kashif MAB; Shakeel Khan MK; Ahmed SH; Asghar MS
Diabetes Obes Metab; 2023 Nov; 25(11):3377-3389. PubMed ID: 37580969
[TBL] [Abstract][Full Text] [Related]
18. Therapies aimed at preservation or restoration of beta cell function in type 1 diabetes.
Keymeulen B
Verh K Acad Geneeskd Belg; 2008; 70(2):85-103. PubMed ID: 18630722
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and antibody responses to the CD3 antibody otelixizumab used in the treatment of type 1 diabetes.
Hale G; Rebello P; Al Bakir I; Bolam E; Wiczling P; Jusko WJ; Vandemeulebroucke E; Keymeulen B; Mathieu C; Ziegler AG; Chatenoud L; Waldmann H
J Clin Pharmacol; 2010 Nov; 50(11):1238-48. PubMed ID: 20147616
[TBL] [Abstract][Full Text] [Related]
20. Anti-CD3 mAbs for treatment of type 1 diabetes.
Kaufman A; Herold KC
Diabetes Metab Res Rev; 2009 May; 25(4):302-6. PubMed ID: 19319985
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
